Treatment Clinical Trials for Prostate Cancer

Clinical trials are research studies that involve people. The clinical trials on this list are for prostate cancer treatment. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 76-100 of 316

  • Nivolumab in Treating Patients with High-Risk Biochemically Recurrent Prostate Cancer

    This phase II trial studies how well nivolumab works in treating patients with prostate cancer that s high-risk to come back after treatment. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
    Location: 5 locations

  • Stereotactic Ablative Body Radiotherapy with or without Neurovascular Sparing in Reducing Erectile Dysfunction in Patients with Localized Prostate Cancer

    This phase II trial studies how well stereotactic ablative body radiotherapy with or without sparing the nerves and vessels to the penis works in reducing erectile dysfunction in patients with prostate cancer that has not spread beyond the prostate. Stereotactic ablative body radiotherapy, also known as stereotactic body radiation therapy, uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Modifying stereotactic ablative body radiotherapy to spare the nerves and vessels to the penis, compared to no modification, may help preserve sexual function after treatment in patients with prostate cancer.
    Location: 5 locations

  • 177Lu-PSMA-R2 in Patients With PSMA Positive Progressive, Metastatic, Castration Resistant Prostate Cancer

    This Phase 1 / 2 study is intended to investigate the safety, tolerability, and radiation dosimetry of 177Lu-PSMA-R2 and further assess preliminary efficacy data in patients with metastatic castration-resistant prostate cancer (mCRPC). The Phase 1 portion of the study will determine the recommended dose of 177Lu-PSMA-R2 for radio-ligand therapy (RLT) of mCRPC, and the Phase 2 portion will expand into approximately 60 patients documenting the preliminary activity (anti-tumor response) of repeated treatments administered, continuing safety assessments and collecting QoL data.
    Location: 6 locations

  • A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer

    The purpose of this study is to: a) establish the recommended phase 2 dose (RP2D) and to evaluate the antitumor activity and safety of niraparib combination therapies (Combinations 1 and 2) and b) to determine the relative bioavailability of niraparib and abiraterone acetate (AA) in combination (Combination 3) in participants with metastatic castration-resistant prostate cancer (mCRPC).
    Location: 6 locations

  • An Investigational Immunotherapy Study of BMS-986249 Alone and in Combination With Nivolumab in Solid Cancers That Are Advanced or Have Spread

    The purpose of this study is to determine whether BMS-986249 both by itself and in combination with Nivolumab is safe and tolerable in the treatment of advanced solid tumors
    Location: 5 locations

  • Olaparib in Treating Patients with High-Risk, Biochemically-Recurrent Prostate Cancer Who Have Undergone Surgery

    This phase II trial studies how well olaparib works in treating patients with high-risk prostate cancer that has had a rise in prostate-specific antigen (PSA) after surgery. A rise in the PSA is a sign that there are tumor cells remaining in the body. Olaparib may help lower PSA and may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: 5 locations

  • A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer

    The study is investigating efficacy, safety and tolerability of DNA-damage Response Agents (or Combinations), in participants with advanced / metastatic solid malignancies whose tumours contain molecular alterations.
    Location: 5 locations

  • A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer

    The purpose of this study is to test the safety and effectiveness of nivolumab with docetaxel in men with advanced castration resistant prostate cancer who have progressed after second-generation hormonal manipulation.
    Location: 7 locations

  • DKN-01 with or without Docetaxel in Treating Patients with Advanced Prostate Cancer with Elevated DKK1

    This phase Ib / IIa trial studies best dose of DKN-01 and how well it works with or without docetaxel in treating patients with prostate cancer with elevated DKK1 that had spread to other places in the body (advanced). DKN-01 is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving DKN-01 with or without docetaxel will work better in treating patients with prostate cancer with elevated DKK1.
    Location: 5 locations

  • Fluciclovine F18 or Gallium Ga 68-labeled PSMA-11 PET / CT in Enhancing Outcomes in Patients with Prostate Adenocarcinoma

    This phase II trial studies how well a positron emission tomography (PET) / computed tomography (CT) scan using fluciclovine F18 compared with a PET / CT scan with gallium Ga 68-labeled PSMA-11 works in planning radiation treatments and enhancing outcomes in patients with prostate adenocarcinoma. Fluciclovine F18 and gallium Ga 68-labeled PSMA-11 are types of tracers, called radiotracers, that are injected and can accumulate in tumor cells to develop images of them during a PET / CT scan. It is not yet known whether giving fluciclovine F18 or gallium Ga 68-labeled PSMA-11 may work better in planning radiation treatments and enhancing outcomes in patients with prostate adenocarcinoma.
    Location: 4 locations

  • Enzalutamide with or without Ribociclib in Treating Patients with Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression

    This partially randomized phase Ib / II trial studies the side effects and best dose of ribociclib when given with enzalutamide and to see how well they work compared to enzalutamide alone in treating patients with castrate-resistant prostate cancer that has spread from the primary site (place where it started) to other places in the body (metastatic), is chemotherapy naive, and retains retinoblastoma expression. Testosterone can cause the growth of prostate cancer cells. Hormone therapy using enzalutamide may fight prostate cancer by blocking the use of testosterone by the tumor cells. Ribociclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether enzalutamide works better when given with or without ribociclib in treating patients with prostate cancer.
    Location: 4 locations

  • Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors

    This is a Phase 1, open label, multicenter, nonrandomized, multiple dose, safety, tolerability, pharmacokinetic and pharmacodynamic study of PF-07220060 administered as a single agent and then in combination with endocrine therapy. In Part 1A, single escalating doses of PF-07220060 alone will be administered to determine the maximum tolerated dose (MTD) and select the recommended phase 2 dose (RP2D). In Part 1B and Part 1C, PF-07220060 will be administered in combination with 1 of 2 endocrine therapies (letrozole and fulvestrant, respectively). Part 1B and Part 1C may be enrolled and conducted in parallel at the completion of Part 1A.
    Location: 4 locations

  • PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

    The purpose of this research study is to evaluate safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of the investigational drug PLX2853 in subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
    Location: 4 locations

  • Study of IGM-8444 as a Single Agent and in Combination With Chemotherapy-based Regimens in Subjects With Solid Cancers

    This study is a first-in-human, Phase 1, multicenter, open-label study to determine the safety, tolerability and pharmacokinetics of IGM-8444 as a single agent and in combination with a chemotherapy-based regimen in patients with relapsed and / or refractory solid tumors.
    Location: 4 locations

  • Study of GNX102 in Patients With Advanced Solid Tumors

    GNX-001 is an open-label, phase 1, multicenter, dose-escalation and expansion study of GNX102 infused every 21 days. Approximately 30 patients may be enrolled in the dose escalation portion of this study. Once the MTD or recommended phase 2 dose (RP2D) has been identified, up to 15 additional patients may be enrolled in one or two expansion cohort(s) at one or two dose levels recommended by the Safety Review Committee) to confirm the safety profile of the RP2D and provide additional information on anti-tumor activity. Patients with adeno- or epithelial-cancers that have a likelihood of GNX102 targeted antigen expression based on previous studies, including colorectal, hepatocellular, non-small cell lung, gastric, breast, pancreatic, cutaneous, acral, or mucosal melanoma, esophageal, prostate, and epithelial uterine cancers, can be screened for enrollment in the study.
    Location: 4 locations

  • Study of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer

    Evaluate the safety and tolerability of AMG 509 in adult subjects and determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D).
    Location: 6 locations

  • A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer

    The reason for this study is to see if the CD73 inhibitor LY3475070 alone or in combination with pembrolizumab is safe and effective in participants with advanced cancer.
    Location: 4 locations

  • Study of ORIC-101 in Combination With Enzalutamide

    The purpose of this study is to establish the recommended phase 2 dose (RP2D), safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of ORIC-101 in combination with enzalutamide (Xtandi®) when administered to patients with metastatic prostate cancer progressing on enzalutamide.
    Location: 5 locations

  • A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC.

    An open-label, multicenter, Phase 1b / 2 study to determine the composite response rate of BXCL701 administered orally and daily, combined wit PEMBRO, in patients with mCRPC enrolled in Stage 2, with either Small Cell Neuroendocrine Prostate Cancer(SCNC)(Cohort A) or adenocarcinoma phenotype (Cohort B). This study will also assess other efficacy parameters as well as the safety of the combined treatment. This study will consist of two (2) stages. Lead-in Stage, in which the safety and tolerability of the combination will be assessed and confirmed. And the Efficacy Stage, in which patients will be treated with BXCL701 combined with PEMBRO.
    Location: 5 locations

  • Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 160 in Subjects With mCRPC

    A study to evaluate the safety and tolerability of AMG 160 and in combination with pembrolizumab in adult subjects with metastatic castration-resistant prostate cancer (mCRPC), and determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D).
    Location: 7 locations

  • A Phase 1 Study of FOR46 in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

    This study will test the safety and efficacy of FOR46 given every 21 days to patients with metastatic castration-resistant prostate cancer. The name of the study drug involved in this study is: FOR46 for Injection (FOR46)
    Location: 4 locations

  • Study to Evaluate CORT125281 in Combination With Enzalutamide in Patients With mCRPC

    This is an open-label, Phase 1 / 2a dose escalation study with an expansion phase to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD), and preliminary efficacy of CORT125281 in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) to identify a recommended dose (RD) for Phase 2 studies.
    Location: 4 locations

  • Androgen-Deprivation Therapy, Apalutamide, and Radiation Therapy Followed by Docetaxel in Treating Patients with Recurrent Prostate Cancer after Radical Prostatectomy

    This phase II trial studies how well androgen-deprivation therapy, apalutamide, and radiation therapy followed by docetaxel work in treating patients with prostate cancer that has come back (recurrent) after radical prostatectomy. Hormone therapy such as androgen-deprivation therapy may fight prostate cancer by blocking the production and interfere with the action of hormones. Apalutamide may help stop or slow the growth of prostate cancer cells. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving androgen-deprivation therapy, apalutamide, radiation therapy followed by docetaxel may work better in treating patients with prostate cancer.
    Location: 4 locations

  • INTense ExeRcise for surviVAL Among Men With Metastatic Prostate Cancer (INTERVAL - GAP4)

    To determine if supervised high intensity aerobic and resistance training increases overall survival compared to self-directed exercise in patients with metastatic prostate cancer.
    Location: 6 locations

  • Study of TAS3681 in Metastatic Castration Resistant Prostate Cancer

    The purpose of this trial is to investigate the safety and tolerability of TAS3681 and to find the maximum tolerated dose of TAS3681.
    Location: 4 locations